Intracelom Hyperthermic Perfusion Therapy Center, Cancer Hospital of Guangzhou Medical College, Guangzhou, 510095, China,
J Cancer Res Clin Oncol. 2013 Dec;139(12):2005-12. doi: 10.1007/s00432-013-1526-x. Epub 2013 Sep 26.
To evaluate the feasibility, safety and preliminary efficacy of B-ultrasound-guided continuous circulatory intrapleural hyperthermic perfusion (IHP) with distilled water (DW) at 48 °C, for the treatment of malignant pleural effusion (MPE).
Prospective, randomized interventional study in China (from December 2008 to December 2011) in adults with MPE originating from disseminated pleural tumor.
thoracotomy or surgical resection, limited encapsulated pleural effusion or extensive pleural adhesions. Patients were randomly divided into DW (12 patients; B-ultrasound-guided IHP with 48 °C DW) and PSS-C (11 patients; B-ultrasound-guided IHP with 45 °C physiological saline solution and cisplatin) groups. Patients were followed up for assessment of objective MPE remission rate, Karnofsky performance scale (KPS) scores and survival duration.
Pleural effusion was controlled in 100 % of patients, and mean KPS score was increased by 40 % after therapy. Patients' median survival times in the DW and PSS-C groups were 13.0 and 12.9 months, respectively. No serious clinical complications were observed. There were no significant differences between groups in the total objective MPE remission rate, mean KPS score change or median survival time, demonstrating the achievement of significant clinical efficacy with our modified IHP.
Intrapleural hyperthermic perfusion with 48 °C DW is feasible, easy to perform and relatively safe. This method may offer excellent local control for patients with MPE secondary to disseminated pleural lesions.
评估在超声引导下对 48°C 蒸馏水(DW)进行持续循环胸膜内热灌注(IHP)治疗恶性胸腔积液(MPE)的可行性、安全性和初步疗效。
在中国进行的前瞻性、随机干预研究(2008 年 12 月至 2011 年 12 月),纳入患有弥漫性胸膜肿瘤所致 MPE 的成年患者。
开胸手术或外科切除、局限性包裹性胸腔积液或广泛胸膜粘连。患者被随机分为 DW 组(12 例;48°C DW 超声引导下 IHP)和 PSS-C 组(11 例;45°C 生理盐水和顺铂超声引导下 IHP)。对患者进行随访,评估客观 MPE 缓解率、卡氏功能状态评分(KPS)和生存时间。
100%的患者胸腔积液得到控制,治疗后 KPS 评分平均增加 40%。DW 组和 PSS-C 组患者的中位生存时间分别为 13.0 个月和 12.9 个月。未观察到严重的临床并发症。DW 组和 PSS-C 组的总客观 MPE 缓解率、KPS 评分变化中位数或中位生存时间均无显著差异,表明改良 IHP 可达到显著的临床疗效。
48°C DW 胸膜内热灌注是可行的、易于操作且相对安全的。对于患有弥漫性胸膜病变所致 MPE 的患者,该方法可能提供出色的局部控制效果。